Pharmaceuticals
Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services
SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. T...
2024-06-25 20:00
2746
NX Group Signs Strategic Partnership Agreement with Controlant of Iceland
- Set to Provide Real-time Monitoring Service for Tracking Cargo Location and Strict Temperature Control - TOKYO, June 25, 2024 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. has signed a strategic partnership agreement withIceland-based Controlant, Inc., a leading provider of real-time monitorin...
2024-06-25 14:00
1946
TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024
* TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-lifein a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors * TiumBio presented interim Phase 1a clinical data of TU7710 and discussed pot...
2024-06-24 20:00
2477
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for T...
2024-06-20 14:51
2100
GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group
* GC Cell and PT Bifarma Adiluhung announced a strategic partnership to
facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell
therapy for HCC into the Indonesian market. YONGIN, South Korea, June 19, 2024
/PRNewswire/ --GC Cell
2024-06-20 08:44
3279
Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. * Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/...
2024-06-19 19:30
2790
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
SHANGHAI, June 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announcedChina's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in...
2024-06-19 19:00
2556
Diabetes Researchers in China Demonstrate Early Insulin Therapy Significant Benefits Cardiovascular Health
BEIJING, June 19, 2024 /PRNewswire/ -- Recently, Professor Jianping Weng of the University of Science and Technology ofChina (USTC) and President of Anhui Medical University and his team of researchers from USTC, Southern Medical University and Peking University published the results of their lat...
2024-06-19 18:10
1923
Tang Prize in Biopharmaceutical Science Honoring Three Scientists
TAIPEI, June 19, 2024 /PRNewswire/ -- In a continuing series of laureate announcements, the Tang Prize Foundationtoday (June 19th) announced the 2024 Tang Prize in Biopharmaceutical Science recipients. The prestigious award has been jointly awarded toJoel F. Habener, Svetlana Mojsov, and Jens Juu...
2024-06-19 12:15
2205
YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China
Strategic Partnership to Advance Gene Editing Technologies in Biomedical Applications SHANGHAI, June 18, 2024 /PRNewswire/ -- YolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery forin vivo gene editing therapies, has partnered with KACTUS, a leading developer se...
2024-06-19 09:00
2201
ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals
BRISBANE, Calif. and SHANGHAI, June 17, 2024 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncology indications, and Asieris Pharmaceuticals, a global biopharmaceutical leader in ...
2024-06-17 22:00
2672
Leads Biolabs Unveils Preclinical Data on LBL-047, a Novel, First-In-Class Long-Acting TACI/Anti-BDCA2 Bispecific Antibody Fusion Protein in an Oral Presentation at EULAR 2024 Congress
NANJING, China, June 17, 2024 /PRNewswire/ -- At the recent European League Against Rheumatism (EULAR) Congress inVienna, Austria, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) delivered an oral presentation on its highly innovative therapeutic candidate LBL-047. LBL-047 is a first-in-class, l...
2024-06-17 18:00
1922
IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024
SHANGHAI and NANJING, China and SAN JOSE, Calif., June 15, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equec...
2024-06-15 22:30
4324
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the initial results from the ongoing first-in-human study of CT0...
2024-06-15 20:50
4154
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...
2024-06-12 19:51
2617
2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations
Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug conjugate (ADC) designed to tr...
2024-06-12 19:31
1887
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO:Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US b...
2024-06-11 20:30
2039
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced that the Company has ent...
2024-06-11 15:57
3931
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and clinically meaningful reductions in liver fat, alanine aminotransferase(ALT), as...
2024-06-11 08:10
2618
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024
HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology E...
2024-06-10 20:00
2518
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 317 media titles]
2026-02-02 10:00
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 284 media titles]
2026-02-01 19:35